Select Page

One of the most exciting sectors to invest in is biotech.

For one, the sector is one of the safest, and most recession-proof. Two, an aging population is demanding more treatments in an effort to live longer lives. As this number continues to grow, we’ll see a need for more medical treatment options.

Three, there’s incredible new innovation in genetics and technology. In fact, over the next several years, genetic testing and gene editing will help to identify and potentially cure diseases. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls.

Four, there are goldmine opportunities to be found.

Look at Fate Therapeutics (FATE), for example. Since bottoming out at $17.60 in 2019, it’s now up to $108.50 a share. Or look at TG Therapeutics (TGTX), which ran from $5 to $52.

All because of new discoveries, innovation, and trial success.

Here are some other top opportunities that could have similar potential.

Top Stock No. 1 – Trillium Therapeutics (TRIL)

Trillium Therapeutics is a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.

There’s still a good deal of opportunity here with TRIL’s CD47 blockers, TTI-671 and TTI-662, an “antigen also known as the “don’t eat me” signal, which is widely expressed on normal cells, but appears in especially high concentrations on cancer cells,” as noted by Med City News.

Sure, the stock ran from 25 cents to $13.61 so far, but there’s plenty of upside remaining here.

Top Stock No. 2 – Myovant Sciences Ltd. (MYOV)

Myovant is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

In late December 2020, MYOV gapped from $23 to $31 on a cancer drug deal worth nearly $4.2 billion. Reportedly, Myovant’s parent Sumitovant Biopharma and Pfizer will work together to develop a treatment for prostate cancer and women’s health. As part of the deal, Myovant will receive an upfront payment of $650 million to develop relugolix, a once daily, oral gonadotropin-releasing hormone receptor antagonist for use in oncology and women’s health in North America, as noted by Marketwatch.

Top Stock No. 3 – Cassava Sciences Inc. (SAVA)

Cassava Sciences is a clinical stage biotechnology company that develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease.

While SAVA already ran from $10 to $60, further progress could send it to new highs.

“We started 2021 with tremendous momentum, led by results of a 6-month interim analysis from an open-label study of simufilam, our drug candidate for Alzheimer’s disease,” said Remi Barbier, President & CEO. “I believe the rest of the year may be equally exciting.”

The company added that “Cassava Sciences’ strategic focus for 2021 is to advance simufilam in a Phase 3 clinical program in Alzheimer’s disease, to expand drug manufacturing capabilities in support of the clinical program, and to continue to lead the Company to deliver the full potential of its product portfolio.”

Top Stock No. 4 — Beam Therapeutics (BEAM)

Beam Therapeutics is working on gene editing techniques that could safer genomic medicine to help provide cures for serious diseases, such as sickle cell disease, acute lymphoblastic leukemia, and potentially liver and ocular diseases.

It’s doing so through base editing, which allows researchers to change individual letters of DNA, and intervene at the most foundational level to treat a wide range of diseases. If existing gene editing approaches are like “scissors” that cut the genome, base editors are “pencils” that enable erasing and rewriting one letter of the genome at a time.

Top Stock No. 5 – Bionano Genomics Inc. (BNGO)

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools.

While the BNGO stock has run significantly so far, there’s still more upside likely.

For one, a recent study found that Saphyr can be used to develop sensitive tests for brain tumors. In fact, it could be effective in locating structural variations in the tumors.

Two, according to FXStreet, “In the company’s symposium about cytogenetics, scientists and doctors shined a bright light on the firm’s ability to help with several types of cancer, such that affecting the liver, eyes, breast, and liver, using the Saphyr optical genome mapping (OGM) system. Using BioNano’s system, they could provide more precise therapies and prognoses. The news comes on top of advances in coronavirus and in the autism spectrum.”

Three, analysts at Oppenheimer have a buy rating on the stock with a $15 price target.

The analysts believe the company’s “recent equity raises which totaled more than $380 million give the company “balance sheet flexibility.” Therefore, the analyst is more focused on the company’s progress than near-term revenue prospects. The strengthened balance sheet allows Bionano to ‘aggressively invest in both commercial infrastructure expansion and next-generation optical imaging technologies.’”